Clinical Trial

Biology of Cerebral Arteriovenous Malformations and Prognosis of Cerebral Arteriovenous Malformations

Study acronym: BioMAV
Recruiting
View on ClinicalTrials.gov →
Summary
The cerebral arteriovenous malformations correspond to the formation of an entanglement of morphologically abnormal vessels called nidus, which shunt the blood circulation directly from the arterial circulation to the venous circulation. The cerebral arteriovenous malformations are an important cause of hemorrhagic stroke. The hypothesis is that cerebral haemorrhage associated with a cerebral arteriovenous malformations would come from peri-nidal micro-vessels, in connection with infiltration of leucocytes and / or defective maintenance of microvascular integrity by platelets.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2018-09-17; most recent amendment 2025-06-19.
Status change: Not Yet Recruiting → Recruiting 2019-01-11
Trial Details
NCT Number NCT03676868
Lead Sponsor Fondation Ophtalmologique Adolphe de Rothschild
Conditions Cerebral Arteriovenous Malformations, Ruptured or Unruptured Cerebral Arteriovenous Malformations
Enrollment 300 participants
Start Date 2018-11-20
Primary Completion 2028-11-19 (estimated)
Study Completion 2028-11-19 (estimated)
Updated on ClinicalTrials.gov 2025-06-25